Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 207M 182M 172M 156M 293M 19.85B 295M 2.05B 796M 10.14B 778M 761M 32.6B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 288M 253M 239M 218M 407M 27.62B 410M 2.86B 1.11B 14.11B 1.08B 1.06B 45.34B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 day-1.36%
1 week-0.97%
Current month-1.45%
1 month-2.59%
3 months-7.04%
6 months-0.88%
Current year-2.87%
1 week 101.1
Extreme 101.1
105.8
1 month 93.2
Extreme 93.2
107.4
Current year 93.2
Extreme 93.2
117.9
1 year 93.2
Extreme 93.2
124.4
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-0.97%-18.85%-58.53% 191M
+0.13%+2.65%+63.34%+115.27% 1,055B
+0.20%+0.46%+50.92%+72.63% 654B
-0.29%+0.14%+19.82%+72.62% 467B
-1.48%-3.02%+38.15%+41.69% 348B
+1.34%+4.46%+22.48%+29.46% 275B
-0.17%-0.32%+12.91%+13.76% 258B
+2.11%+7.51%+51.88%+54.14% 224B
+0.83%+0.55%+34.64%+99.77% 187B
-0.23%-3.08%-28.31%-61.32% 171B
Average -0.14%+0.66%+24.70%+37.95% 363.85B
Weighted average by Cap. +0.08%+1.32%+39.97%+68.57%

Financials

2024 2025
Net sales 10.7B 87M 76.34M 72.1M 65.71M 123M 8.34B 124M 863M 334M 4.26B 327M 320M 13.69B 12.54B 102M 89.48M 84.51M 77.01M 144M 9.77B 145M 1.01B 392M 4.99B 383M 375M 16.05B
Net income 521M 4.24M 3.72M 3.51M 3.2M 5.99M 406M 6.03M 42.01M 16.27M 207M 15.9M 15.56M 667M 947M 7.69M 6.75M 6.38M 5.81M 10.88M 738M 10.96M 76.31M 29.56M 377M 28.89M 28.27M 1.21B
Net Debt 10B 81.27M 71.32M 67.36M 61.38M 115M 7.79B 116M 806M 312M 3.98B 305M 299M 12.79B 9.96B 81M 71.08M 67.13M 61.18M 115M 7.76B 115M 803M 311M 3.97B 304M 298M 12.75B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
27/09/26 BDT 101.60 -1.36% 31,650
24/09/26 BDT 103.00 -0.77% 107,014
23/09/26 BDT 103.80 +2.47% 81,563
22/09/26 BDT 101.30 -0.39% 59,224
21/09/26 BDT 101.70 -0.88% 48,069
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock